# Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil

> **NCT05256537** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Ronald Paquette** · enrollment: 60 (actual)

## Conditions studied

- Hematologic Neoplasms

## Interventions

- **OTHER:** Omission of the drug mycophenolate mofetil

## Key facts

- **NCT ID:** NCT05256537
- **Lead sponsor:** Ronald Paquette
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-04-26
- **Primary completion:** 2024-09-20
- **Final completion:** 2026-08-07
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05256537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05256537, "Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil". Retrieved via AI Analytics 2026-08-16 from https://api.ai-analytics.org/clinical/NCT05256537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*